Delay and attrition before treatment initiation among MDR-TB patients in five districts of Gujarat, India

被引:16
|
作者
Shewade, H. D. [1 ,2 ]
Shringarpure, K. S. [3 ]
Parmar, M. [4 ]
Patel, N. [3 ]
Kuriya, S. [3 ]
Shihora, S. [3 ]
Ninama, N. [3 ]
Gosai, N. [3 ]
Khokhariya, R. [3 ]
Popat, C. [3 ]
Thanki, H. [4 ]
Modi, B. [5 ]
Dave, P. [6 ]
Baxi, R. K. [3 ]
Kumar, A. M. V. [1 ,2 ]
机构
[1] Int Union TB & Lung Dis, South East Asia Off, New Delhi 110016, India
[2] The Union, Paris, France
[3] Med Coll, Dept Prevent & Social Med, Vadodara, India
[4] World Hlth Org Country Off India, New Delhi, India
[5] Gujarat Med Educ & Res Soc, Med Coll & Hosp, Dept Community Med, Gandhinagar, India
[6] Govt Gujarat, Dept Hlth & Family Welf, Gandhinagar, India
来源
PUBLIC HEALTH ACTION | 2018年 / 8卷 / 02期
关键词
multidrug-resistant tuberculosis; prevention and control; operational research; India; initial loss to follow-up;
D O I
10.5588/pha.18.0003
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Setting: Gujarat, a state in west India. Background: Although treatment initiation has been improving among patients diagnosed with multidrug-resistant tuberculosis (MDR-TB) in programme settings, it has still not reached 100%. Objectives: To determine pre-treatment attrition (not initiated on treatment within 6 months of diagnosis), delay in treatment initiation (>7 days from diagnosis) and associated factors among MDR-TB patients diagnosed in 2014 in five selected districts served by two genotypic drug susceptibility testing (DST) facilities and a drug-resistant TB centre in Gujarat. Design: This was a retrospective cohort study involving record review. Results: Among 257 MDR-TB patients, pre-treatment attrition was seen in 20 (8%, 95% CI 5-12). Patients with 'follow-up sputum-positive' as their DST criterion and sputum smear microscopy status 'unknown' at the time of referral for DST were less likely to be initiated on treatment. The median delay to treatment initiation was 8 days (interquartile range 6-13). Patients referred for DST from medical colleges were more likely to face delays in treatment initiation. Conclusion: The Gujarat TB programme is performing well in initiating laboratory-confirmed MDR-TB patients on treatment. However, there is further scope for reducing delay.
引用
收藏
页码:59 / 65
页数:7
相关论文
共 50 条
  • [31] Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia
    Shin, S. S.
    Pasechnikov, A. D.
    Gelmanova, I. Y.
    Peremitin, G. G.
    Strelis, A. K.
    Mishustin, S.
    Barnashov, A.
    Karpeichik, Y.
    Andreev, Y. G.
    Golubchikova, V. T.
    Tonkel, T. P.
    Yanova, G. V.
    Yedilbayev, A.
    Rich, M. L.
    Mukherjee, J. S.
    Furin, J. J.
    Atwood, S.
    Farmer, P. E.
    Keshavjee, S.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2007, 11 (12) : 1314 - 1320
  • [32] Screening with GenoTypeVR MTBDRplus shortens the time to MDR-TB treatment initiation but does not change outcomes
    Mendoza-Ticona, A.
    Mitnick, C. D.
    Obregon, G.
    Alarcon, V.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2023, 27 (12) : 949 - 951
  • [33] Association of MDR-TB isolates with clinical characteristics of patients from Northern region of India
    Gupta, A.
    Nagaraja, M. R.
    Kumari, P.
    Singh, G.
    Raman, R.
    Singh, S. K.
    Anupurba, S.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2014, 32 (03) : 270 - 276
  • [34] Study of Adverse Drug Reactions and Treatment Outcome in Mdr-Tb Patients Registered at Dots Plus Site, Ssg Hospital, Baroda, Gujarat
    Vithalapara, K. V.
    Trivedi, N. A.
    Makwana, M. Z.
    Patel, K. R.
    Leuva, A. T.
    INDIAN JOURNAL OF PHARMACOLOGY, 2014, 46 : S21 - S22
  • [35] Status of multidrug resistant tuberculosis (MDR-TB) among the Sahariya tribe of North Central India
    Prakash, Ravi
    Kumar, Dilip
    Gupta, Vinod K.
    Jain, Sanjay
    Chauhan, Devendra S.
    Tiwari, Pramod K.
    Katoch, Vishwa M.
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2016, 9 (03) : 289 - 297
  • [36] Retrospective audit of patients treated for MDR-TB in re-treatment category
    Saeed, Waseem
    Naseem, Arshad
    Ahmed, Jamal
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2013, 63 (01) : S70 - S74
  • [37] Linezolid-induced peripheral neuropathy in patients receiving MDR-TB treatment
    Skyllberg, Erik
    Young, Rebekah
    Sharma, Akhilesh
    Chen, Christabelle
    Tiberi, Simon
    White, Veronica
    Kunst, Heinke
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [38] Shortening MDR-TB treatment: is treating more patients with fewer drugs better?
    Akkerman, O. W.
    Tiberi, S.
    Alffenaar, J-W.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2021, 25 (06) : 419 - 420
  • [39] Treatment Results of Multidrug Resistant Tuberculosis (MDR-TB) Patients in the Aegean Region
    Karaman, Onur
    Varol, Yelda
    Bicmen, Can
    Akarca, Tulay
    Dereli, Sevket
    Ozbakir, Didem
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [40] Occurrence and predictors of adverse events associated with Linezolid in the treatment of patients with MDR-TB
    Oehadian, A.
    Bastos, M. L.
    Centis, R.
    D'Ambrosio, L.
    Migliorie, G. B.
    Santoso, P.
    Ruslami, R.
    Menzies, D.
    PULMONOLOGY, 2024, 30 (02): : 184 - 187